Clinical trials: Atomoxetine Hydrochloride
Alzheimer Disease
Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease
This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve…
- Trial name
- NCT00191009
- Testing
- atomoxetine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Cancer, Cognitive Late Effects
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.
- Trial name
- NCT00255138
- Testing
- Atomoxetine
- Where
- United States
- Sponsor
- Temple University
Attention Deficit Hyperactivity Disorder, Reading Disorder
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with…
- Trial name
- NCT00191906
- Testing
- Atomoxetine Hydrochloride
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company